Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.

Inclusion Criteria: 1. Patients with R/R DLBCL or FL with all of the following: Failure of \>/= 2 prior lines of therapy, or an autologous or allogeneic stem cell transplant. Prior failure of CAR-T or not eligible for CAR-T cells. 2. Tumor biopsy positive for CD19 or CD20 at \>/= 1% by immunohistochemistry or flow cytometry. 3. Age 18-80 years. 4. Karnofsky performance status \>/=60%. 5. Absolute neutrophil count \>/=500/mm3 and platelet count \>/=50,000/mm3. 6. Serum creatinine clearance (CrCl) \>/=30 ml/min, estimated using the Cockcroft-Gault equation: Estimated creatinine clearance = (140-age \[years\]) x weight (kg) (x Fa) / serum creatinine (mg/dL) x 72 \[a where F=0.85 for females and F=1 for males\]. 7. Adequate hepatic function (ALT and/or AST \/=2,000 IU/mL), or hepatitis C (detectable viral load by HCV RNA PCR) 7. Active infection requiring parenteral antibiotics. 8. HIV infection. 9. Treatment within prior 2 weeks with any anti-cancer agent, investigational or approved. 10. Active central nervous system (CNS) involvement (untreated parenchymal brain metastasis or positive cytology of cerebrospinal fluid). 11. Life expectancy \